Related Experiment Video
Updated: Feb 9, 2026

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
Published on: July 15, 2015
Patient-centered practice in elderly myeloma patients: an overview and consensus from the European Myeloma Network
Alessandra Larocca1, Sandra Maria Dold2, Sonja Zweegman3
1Myeloma Unit, Division of Hematology, University of Turin, Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino, Turin, Italy. alelarocca@hotmail.com.
Abstract:
Multiple myeloma is a disease typical of the elderly, and, because of the increase in life expectancy of the general population, its incidence is expected to grow in the future. Elderly patients represent a particular challenge due to their marked heterogeneity. Many new and highly effective drugs have been introduced in the last few years and results from clinical trials are promising. Besides the availability of novel agents, a careful evaluation of elderly patients showed to be a key factor for the success of therapy. A geriatric assessment is a valid strategy to better stratify patients. In particular, different scores are available today to appropriately assess elderly patients and define their fitness/frailty status. The choice of treatment-transplantation, triplets, doublets, or reduced-dose therapies including novel agents-should depend on the patient's fitness status (fit, intermediate-fit or frail). Second-generation novel agents have also been evaluated as salvage therapy in the elderly, and these new agents certainly represent a further step forward in the treatment armamentarium for elderly patients with multiple myeloma.
Related Concept Videos
Patient-centered Care
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
Drug Dosing: Geriatric Patients
Drug Dosing: Obese Patients
Pharmacodynamics in Geriatric Patients: Effects of Age
Pharmacokinetics in Pediatric Patients: Drug Excretion

